Status:
COMPLETED
Efficacy and Safety Study of CD 2027 Spray in Subjects With Plaque-type Psoriasis
Lead Sponsor:
Galderma R&D
Conditions:
Psoriasis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This was a multicenter, randomized, vehicle-controlled, double-blind parallel group study to evaluate the efficacy and safety of CD 2027 Oily Spray applied twice daily for 8 weeks in participants with...
Eligibility Criteria
Inclusion
- Participant has a diagnosis of plaque-type psoriasis up to 20% of body surface area (BSA) involved excluding the scalp, with a Global Severity Score of at least 3 (moderate) at Screening
- Participant presents with a representative target lesion that is at least 16 cm² in area, is located on the non-bony areas of the skin, has a Scaling Score up to 2 (moderate), has a DSS of at least 4
Exclusion
- Other type of psoriasis (other than plaque)
- Significant abnormal lab findings
- Hypercalcemia
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2009
Estimated Enrollment :
88 Patients enrolled
Trial Details
Trial ID
NCT00763555
Start Date
September 1 2008
End Date
March 1 2009
Last Update
August 23 2022
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Minnesota Clinical Study Center
Fridley, Minnesota, United States, 55432
2
Tennessee Clinical Research Center
Nashville, Tennessee, United States, 37215
3
Stratica Medical
Edmonton, Alberta, Canada, T5K1X3
4
Ultranova Skincare
Barrie, Ontario, Canada, L4M6L2